cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 3, 2009, Pages 884-891

  Vandeput, Fabrice ^a   Krall, Judith ^a   Ockaili, Ramzi ^b   Salloum, Fadi N ^b   Florio, Vincent ^c   Corbin, Jackie D ^d   Francis, Sharron H ^d   Kukreja, Rakesh C ^b   Movsesian, Matthew A ^a,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c OMEROS CORPORATION   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE V; SILDENAFIL;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CYTOSOL; DRUG SELECTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE; HEART PROTECTION; HUMAN; HUMAN TISSUE; HYDROLYSIS; MALE; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; CORONARY VESSELS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; CYTOSOL; HEART FAILURE; HUMANS; HYDROLYSIS; MALE; MICE; MICE, INBRED ICR; MICROSOMES; MYOCARDIUM; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SUBCELLULAR FRACTIONS; SULFONES;

EID: 70349085833     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154468     Document Type: Article

References (40)

1. Bender AT (2007) Calmodulin-stimulated cyclic nucleotide phosphodiesterases, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo JA, Francis SH, and Houslay MD eds) pp 35-54, CRC Press, Boca Raton, FL.
2. Bischoff E (2004) Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 16 (Suppl 1):S11-S14.
3. Castro LR, Verde I, Cooper DM, and Fischmeister R (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113:2221-2228. (Pubitemid 43755145)
4. Das A, Ockaili R, Salloum F, and Kukreja RC (2004) Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 286:H1455-H1460. (Pubitemid 38381155)
5. Das A, Xi L, and Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955. (Pubitemid 40491117)
6. Das A, Xi L, and Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585.
7. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, Zhao A, Sadoshima J, Blaxall BC, Berk BC, et al. (2005a) Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 111:2469-2476. (Pubitemid 40696135)
8. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina CA, Sadoshima J, Blaxall BC, et al. (2005b) A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci U S A 102:14771-14776. (Pubitemid 41457131)
9. Drexler H, Kästner S, Strobel A, Studer R, Brodde OE, and Hasenfuss G (1998) Expression, activity and functional significance of inducible nitric oxide synthase in the failing human heart. J Am Coll Cardiol 32:955-963. (Pubitemid 28459584)
10. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, and Vandecasteele G (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99:816-828. (Pubitemid 44556380)
11. Fisher PW, Salloum F, Das A, Hyder H, and Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111: 1601-1610. (Pubitemid 40525159)
12. Francis SH and Corbin JD (2005) Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. Expert Opin Drug Metab Toxicol 1:283-293.
13. Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Bount MA, and Corbin JD (2007) Phosphodiesterase 5: molecular characteristics relating to structure, function and regulation, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo JA, Francis SH, and Houslay MD eds) pp 131-164, CRC Press, Boca Raton.
14. Hambleton R, Krall J, Tikishvili E, Honeggar M, Ahmad F, Manganiello VC, and Movsesian MA (2005) Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 280:39168-39174. (Pubitemid 41713868)
15. Hassan MA and Ketat AF (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5:10.
16. Hayes JS, Brunton LL, and Mayer SE (1980) Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem 255:5113-5119. (Pubitemid 10015830)
17. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, and Paulus WJ (1999) Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99:3009-3016. (Pubitemid 29270430)
18. Jurevicius J, Skeberdis VA, and Fischmeister R (2003) Role of cyclic nucleotide phosphodiesterase isoforms in cAMP compartmentation following beta2- adrenergic stimulation of ICa,L in frog ventricular myocytes. J Physiol 551:239-252. (Pubitemid 37062925)
19. Kambayashi J, Shakur Y, and Liu Y (2007) Bench to bedside: multiple actions of the PDE3 inhibitor cilostazol, in Cyclic Nucleotide Phosphodiesterases in Health and Disease (Beavo JA, Francis SH, and Houslay MD eds) pp 627-648, CRC Press, Boca Raton, FL.
20. Kass DA, Champion HC, and Beavo JA (2007) Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 101:1084-1095.
21. Kincaid RL and Manganiello VC (1988) Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates. Methods Enzymol 159:457-470.
22. Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen Y, Lakatta EG, and Xiao RP (1999) G(i) protein-mediated functional compartmentalization of cardiac beta(2)- adrenergic signaling. J Biol Chem 274:22048-22052. (Pubitemid 29360046)
23. 2+ channel regulation in adult rat ventricular myocytes. Role of phosphodiesterases. Circ Res 102:1091-1100.
24. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, et al. (2006) Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/ cGMP-dependent pathway. Circ Res 98:226-234. (Pubitemid 43755354)
25. Movsesian M, Stehlik J, Vandeput F, and Bristow MR (2008) Phosphodiesterase inhibition in heart failure. Heart Fail Rev, doi: 10.1007/s10741-008-9130-x.
26. 2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 65: 1141-1144.
27. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, et al. (2007) Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 116:238-248. (Pubitemid 47196559)
28. Nikolaev VO, Bünemann M, Schmitteckert E, Lohse MJ, and Engelhardt S (2006) Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1- adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res 99:1084-1091. (Pubitemid 44729932)
29. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, and Rich TC (2006) Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments. J Gen Physiol 128:3-14. (Pubitemid 43967547)
30. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, et al. (2009) Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119:408-416.
31. Rochais F, Abi-Gerges A, Horner K, Lefebvre F, Cooper DM, Conti M, Fischmeister R, and Vandecasteele G (2006) A specific pattern of phosphodiesterases controls the cAMP signals generated by different Gs-coupled receptors in adult rat ventricular myocytes. Circ Res 98:1081-1088. (Pubitemid 43755230)
32. Salloum F, Yin C, Xi L, and Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595-597. (Pubitemid 36417692)
33. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, et al. (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294:H1398-H1406.
34. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, and Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214-222. (Pubitemid 40321358)
35. Vandeput F, Wolda SL, Krall J, Hambleton R, Uher L, McCaw KN, Radwanski PB, Florio V, and Movsesian MA (2007) Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282:32749-32757. (Pubitemid 350159317)
36. Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, and Lakatta EG (1999) Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res 84:43-52. (Pubitemid 29074879)
37. 2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem 269:19151-19156.
38. Yan C, Miller CL, and Abe J (2007) Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100:489-501. (Pubitemid 46673258)
39. ZaccoloM(2006) Phosphodiesterases and compartmentalized cAMP signalling in the heart. Eur J Cell Biol 85:693-697.
40. Zoraghi R, Francis SH, and Corbin JD (2007) Critical amino acids in phosphodiesterase- 5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry 46:13554-13563. (Pubitemid 350209951)